2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
The primary objective of this prospective study in subjects with severe emphysema is to evaluate the utility of the AeriSeal System to occludecollateral air channels in a target lung lobe with collateral ventilation (CV+) and convert the target lung…